Drugs / T320
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07434609 | Dec 2027 → Dec 2029 expected | — | Nanolattix Biotechnology Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | T320 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07434609 ↗ |
| Modality | Other / unclassified | “Anti-Tissue Factor Antibody-Drug Conjugate” NCT07434609 ↗ |